Mark Cuban's Cost Plus Drugs targets rare disease drug manufacturing costs

Mark Cuban's Cost Plus Drugs announced plans to reduce manufacturing costs for custom rare disease drugs and n-of-1 gene therapies, potentially disrupting a niche but high-cost market. The initiative is early-stage, with details on technology and partnerships unclear. If successful, it could lower prices for ultra-orphan treatments and expand access, but regulatory and technical hurdles remain.